Iwodi Cornelius, Gberikon Grace M, Ogbonna Innocent Okonkwo, Agada Emmanuel O
Department of Microbiology, College of Biological Sciences, Joseph Sarwuan Tarka University, Makurdi, Nigeria.
Department of Microbiology, Joseph Sarwuan Tarka University, Makurdi, Nigeria.
Braz J Microbiol. 2024 Mar;55(1):447-454. doi: 10.1007/s42770-024-01260-x. Epub 2024 Feb 3.
The aim of this study was to investigate multi-drug-resistant (MDR) Escherichia coli in urine of adult male patients with enlarged prostate. Three hundred and sixty-eight samples of urine and blood were collected. Escherichia coli was isolated, purified, and identified and prostate-specific antigen (PSA) was determined. Multi-drug resistance test and specific drug resistance genes were assessed. Prevalence of Escherichia coli was high (38.5%) in patients with PSA of 60-79 ng ml and 60% were MDR. The isolates showed highest resistance to tetracycline (53.3.0%) and least to cephalosporins (5%). They had intL and gyrA genes, which are integron, and quinolone resistance genes and sul1 and sul2 which are sulphonamide resistance-associated genes. Levofloxacin, ertapenem, and Augmentin (100% susceptibilities) were considered choice drugs for treatment of Escherichia coli infection in patients with elevated PSA.
本研究的目的是调查成年前列腺增生男性患者尿液中的耐多药(MDR)大肠杆菌。收集了368份尿液和血液样本。分离、纯化并鉴定了大肠杆菌,同时测定了前列腺特异性抗原(PSA)。评估了多重耐药试验和特定耐药基因。PSA为60 - 79 ng/ml的患者中大肠杆菌的患病率较高(38.5%),其中60%为耐多药菌。分离菌株对四环素的耐药性最高(53.3%),对头孢菌素的耐药性最低(5%)。它们具有整合子的intL和gyrA基因以及喹诺酮耐药基因,还有与磺胺耐药相关的sul1和sul2基因。左氧氟沙星、厄他培南和奥格门汀(敏感性均为100%)被认为是治疗PSA升高患者大肠杆菌感染的首选药物。